uniQure announces closing of commercialization and license agreement with CSL Behring

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to uniQure announces closing of commercialization and license agreement with CSL Behring

uniQure BV (QURE) Risk/Reward 'Heavily Skewed To The Upside' - Raymond James

May 6, 2021 9:44 AM EDT

Raymond James analyst Danielle Brill reiterated a Strong Buy rating and $75.00 price target on uniQure BV (NASDAQ: QURE) after announcing the licensing agreement with CSL Behring for its HemB gene therapy (etranacogene dezaparvovec (EtranaDez)) has closed.

"In our view, the hemophilia-B gene... More

uniQure (QURE) Removes 'Overhang' With CSL Deal Closure - Stfel

May 6, 2021 8:31 AM EDT

Stifel analyst Paul Matteis said the closing of the CSL deal removes an overhang from uniQure (NASDAQ: QURE).

The analyst commented, "We are reiterating our Buy Rating on QURE after the closing of the CSL deal for AMT-061, QURE's HemeB GTx where the... More